Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 10:14:1145860.
doi: 10.3389/fphar.2023.1145860. eCollection 2023.

Periprostatic adipose tissue (PPAT) supernatant from obese mice releases anticontractile substances and increases human prostate epithelial cell proliferation: the role of nitric oxide and adenosine

Affiliations

Periprostatic adipose tissue (PPAT) supernatant from obese mice releases anticontractile substances and increases human prostate epithelial cell proliferation: the role of nitric oxide and adenosine

Gabriela Reolon Passos et al. Front Pharmacol. .

Abstract

Background: The prostate gland is surrounded by periprostatic adipose tissue (PPAT) that can release mediators that interfere in prostate function. In this study, we examined the effect of periprostatic adipose tissue supernatant obtained from obese mice on prostate reactivity in vitro and on the viability of human prostatic epithelial cell lines. Methods: Male C57BL/6 mice were fed a standard or high-fat diet after which PPAT was isolated, incubated in Krebs-Henseleit solution for 30 min (without prostate) or 60 min (with prostate), and the supernatant was then collected and screened for biological activity. Total nitrate and nitrite (NOx-) and adenosine were quantified, and the supernatant was then collected and screened for biological activity. NOx- and adenosine were quantified. Concentration-response curves to phenylephrine (PE) were obtained in prostatic tissue from lean and obese mice incubated with or without periprostatic adipose tissue. In some experiments, periprostatic adipose tissue was co-incubated with inhibitors of the nitric oxide (NO)-cyclic guanosine monophosphate pathway (L-NAME, 1400W, ODQ), adenylate cyclase (SQ22536) or with adenosine A2A (ZM241385), and A2B (MRS1754) receptor antagonists. PNT1-A (normal) and BPH-1 (hyperplasic) human epithelial cells were cultured and incubated with supernatant from periprostatic adipose tissue for 24, 48, or 72 h in the absence or presence of these inhibitors/antagonists, after which cell viability and proliferation were assessed. Results: The levels of NOx- and adenosine were significantly higher in the periprostatic adipose tissue supernatant (30 min, without prostate) when compared to the vehicle. A trend toward an increase in the levels of NOX was observed after 60 min. PPAT supernatant from obese mice significantly reduced the PE-induced contractions only in prostate from obese mice. The co-incubation of periprostatic adipose tissue with L-NAME, 1400W, ODQ, or ZM241385 attenuated the anticontractile activity of the periprostatic adipose tissue supernatant. Incubation with the supernatant of periprostatic adipose tissue from obese mice significantly increased the viability of PNT1-A cells and attenuated expression of the apoptosis marker protein caspase-3 when compared to cells incubated with periprostatic adipose tissue from lean mice. Hyperplastic cells (BPH-1) incubated with periprostatic adipose tissue from obese mice showed greater proliferation after 24 h, 48 h, and 72 h compared to cells incubated with culture medium alone. BPH-1 cell proliferation in the presence of PPAT supernatant was attenuated by NO-signaling pathway inhibitors and by adenosine receptor antagonists after 72 h. Conclusion: NO and adenosine are involved in the anticontractile and pro-proliferative activities of periprostatic adipose tissue supernatant from obese mice. More studies are needed to determine whether the blockade of NO and/or adenosine derived from periprostatic adipose tissue can improve prostate function.

Keywords: PPAT; adenosine; benign prostatic hyperplasia; cell proliferation; nitric oxide; obesity; prostate.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The schematic representation of the bioassay protocols. Periprostatic adipose tissue (PPAT) from obese mice was weighed (∼40 mg), incubated in Krebs-Henseleit solution (30 min, 37°C) with carboxygen, and the supernatant was then collected. Prostate segments from lean or obese mice were incubated (30 min, 37°C without and with PPAT supernatant, in the absence (A) or presence (B) of NOS inhibitors (L-NAME, a non-selective inhibitor; 1400W, an inhibitor of inducible NOS; ODQ, an inhibitor of soluble guanylate cyclase, and ZM241385, adenosine A2A receptor antagonist).
FIGURE 2
FIGURE 2
General characteristics. (A) Total body weight, (B) prostate weight, and (C) periprostatic adipose tissue (PPAT) weight. The prostate and PPAT weights were normalized relative to the tibial length of the mice. The columns are the mean ± SD of six mice/group. *p < 0.05, compared to lean mice. (D) Glucose tolerance test (GTT), with glucose concentrations expressed in mg/dL. Blood samples were obtained from lean and obese mice at 0, 15, 30, 60, 90, and 120 min. (E) The area under the glucose curve (A.U.C.) derived from the GTT test for lean and obese mice. (F) Insulin tolerance test (ITT), with glucose concentrations expressed in mg/dL. Blood samples were obtained from lean and obese mice at 0, 5, 10, 15, 20, 25, and 30 min. (G) Glucose decay constant (κITT; %/min). In panels (EG), the points and columns represent the mean ± SD (n = 5 mice/group). *p < 0.05 compared to lean mice in all cases (Student’s unpaired t-test).
FIGURE 3
FIGURE 3
Hematoxylin-eosin-stained sections of prostate and periprostatic adipose tissue (PPAT) at different magnifications. 10x (A,D), 20x (B,E), and 40x (C,F,G, and H). Scale bars in micrometers. (I) Adipocyte area. The area of 10 adipocytes of PPAT per slide was calculated and the results were expressed as the mean ± SD (n = 5). *p < 0.0007 compared to adipocytes from lean mice. (J) The representative photomicrographs of prostate tissue stained for the cell proliferation marker Ki-67. (K) Quantitative analysis of proliferating prostatic cells in lean and obese mice. The columns represent the mean ± SD (n = 5). *p < 0.05 compared to lean mice (Student’s unpaired t-test).
FIGURE 4
FIGURE 4
Total nitrite and nitrate (NOx-) and adenosine quantification. NOx were quantified in PPAT supernatant from obese mice or in the vehicle (KHS) for 30 min (A), without prostate) and 60 min (B), with prostate) at 37°C and continuously bubbled with carboxygen. (C) Adenosine was quantified in PPAT supernatant from obese mice (without prostate, 30 min) or in the vehicle (KHS) at 37°C and continuously bubbled with carboxygen. *p < 0.05 for–obese PPAT vs. + obese PPAT. The columns represent the mean ± SD (n = 5–6) (Student’s unpaired t-test).
FIGURE 5
FIGURE 5
Functional reactivity assays. (A) Concentration-response curves to phenylephrine (Phe, n = 7) or (B) Electrical field stimulation of the prostatic tissue from lean (n = 6) and obese (n = 10) mice in the absence (KHS alone) and the presence of supernatant from periprostatic adipose tissue (+PPAT) of obese mice. PPAT from obese mice was incubated with KHS for 30 min at 37°C with carboxygen, after which the supernatant was collected and tested for biological activity. The points and columns represent the mean ± SD of the indicated number of mice. *p < 0.05 for control vs. obese and # p < 0.05 for obese vs. obese + PPAT (Student’s unpaired t-test, or one-way ANOVA followed by the Bonferroni multiple comparisons test.) The experiment with PPAT from lean animals was not tested for ethical and cost reasons involved.
FIGURE 6
FIGURE 6
Functional reactivity assays in the presence of inhibitors/antagonists. Concentration-response curves to phenylephrine (Phe) in prostatic tissue from obese mice incubated in the absence or presence of periprostatic adipose tissue (PPAT) alone (+PPAT), and with (A) L-NAME, a non-selective NOS inhibitor (n = 6), (B) 1400W, an inhibitor of inducible NOS (n = 5), (C) ODQ, a soluble guanylate cyclase inhibitor (n = 6), and (D) ZM241385, an adenosine A2A receptor antagonist (n = 5). The points represent the mean ± SD of the indicated number of mice. *p < 0.05 for–PPAT vs. + PPAT and # p < 0.05 for + PPAT vs. + PPAT with inhibitors (one-way ANOVA followed by the Bonferroni multiple comparisons test).
FIGURE 7
FIGURE 7
Cell-based assays with normal epithelial cells. Normal human epithelial cells (PNT1-A) viability (% of the vehicle) in the presence of lean periprostatic adipose tissue (+ Lean PPAT) and obese periprostatic adipose tissue (+Obese). (A) Cell proliferation in PNT1-A in the absence (vehicle) and presence of supernatant from periprostatic adipose tissue (PPAT) of obese mice. The cells were incubated with and without PPAT for 24 h, 48 h, and 72 h, after which cell proliferation was assessed using CyQUANT® assay kits. (B) The columns represent the mean ± SD (Student´s unpaired t-test or one-way ANOVA followed by the Bonferroni multiple comparisons test) of the three separate occasions. Each time, the PPAT was obtained from two animals. Therefore, in panels (A) and (B), a total of N = 6 animals were included in this assay. The effect of PPAT supernatant on the level of cleaved caspase-3 protein in PNT1-A cells. The level of cleaved caspase-3 was normalized relative to caspase-3 protein expression levels, and the values are expressed in arbitrary units (a.u.). (C) Representative images of the WB analysis showing + obese PPAT and Vehicle. (D) The columns represent the mean ± SD, N = 6 animals (Student´s unpaired t-test or one-way ANOVA followed by the Bonferroni multiple comparisons test).
FIGURE 8
FIGURE 8
Cell-based assays with hyperplastic epithelial cells. Cell proliferation in a human benign prostatic hyperplasia cell line (BPH-1) in the absence (vehicle KHS) and presence of supernatant from periprostatic adipose tissue (PPAT) of obese mice (+PPAT) incubated alone or with (A) L-NAME, a non-selective NOS inhibitor, (B) 1400W, an inhibitor of inducible NOS, (C) ODQ, a soluble guanylate cyclase inhibitor, (D) SQ 22,536, an inhibitor of adenylate cyclase, (E) ZM241385, an adenosine A2A receptor antagonist, and (F) MRS 1754, an adenosine A2B receptor antagonist. (G) The proliferation of BPH-1 cells in the presence of inhibitors or antagonists alone. None of the compounds had any effect on cell proliferation at the concentrations tested. In all cases, cell proliferation was assessed using CyQUANT® assay kits. The columns represent the mean ± SD of three to four occasions (each done in triplicate). Each time, the PPAT was obtained from two animals. Therefore, a total of N = six to eight animals were included in this assay. *p < 0.05 for the vehicle vs. + PPAT and # p < 0.05 for + PPAT vs. + PPAT plus inhibitors (two-way ANOVA followed by the Bonferroni multiple comparisons test).

Similar articles

Cited by

References

    1. Abrams P., Chapple C., Khoury S., Roehrborn C., de la Rosette J. International Consultation on New Developments in Prostate Cancer and Prostate Diseases (2013). Evaluation and treatment of lower urinary tract symptoms in older men. J. Urol. 189 (1), S93–S101. 10.1016/j.juro.2012.11.021 - DOI - PubMed
    1. Alexandre E. C., Calmasini F. B., Sponton A. C. D. S., de Oliveira M. G., André D. M., Silva F. H., et al. (2018). Influence of the periprostatic adipose tissue in obesity-associated mouse urethral dysfunction and oxidative stress: Effect of resveratrol treatment. Eur. J. Pharmacol. 5 (836), 25–33. 10.1016/j.ejphar.2018.08.010 - DOI - PubMed
    1. Baltieri N., Guizoni D. M., Victorio J. A., Davel A. P. (2018). Protective role of perivascular adipose tissue in endothelial dysfunction and insulin-induced vasodilatation of hypercholesterolemic LDL receptor-deficient mice. Front. Physiol. 9, 229. 10.3389/fphys.2018.00229 - DOI - PMC - PubMed
    1. Bauer S. R., Harrison S. L., Cawthon P. M., Senders A., Kenfield S. A., Suskind A. M., et al. (2022). Longitudinal changes in adiposity and lower urinary tract symptoms among older men. J. Gerontol. A Biol. Sci. Med. Sci. 6 (10), 2102–2109. 10.1093/gerona/glab227 - DOI - PMC - PubMed
    1. Bayliss M., Wu C., Newgreen D., Mundy A. R., Fry C. H. (1999). A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J. Urol. 162 (5), 1833–1839. 10.1016/s0022-5347(05)68247-x - DOI - PubMed